🏢 官网IRRVMDCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:05:29·⟳ 抓取 04:08:50 +3m21s·⚡ 决策 07-30 04:38:05 +29m15s·89.6 天前
Revolution Medicines宣布二季度财报披露和电话会日期
本次只是公司预告将在2026-08-05盘后披露二季度财报并召开电话会，没有披露业绩数据、临床进展、监管进展或商业化增量。
📄 原文RVMD↗ 原文
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinica…
不做 Revolution Medicines（RVMD.US）
仅为财报披露日期和电话会日程通知，没有业绩、指引、临床或监管新增事实，无法形成同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-29 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司预告将在2026-08-05盘后披露二季度财报并召开电话会，没有披露业绩数据、临床进展、监管进展或商业化增量。
主要风险
- 真正可交易的信息要等财报、管线更新或管理层指引实际披露后再判断。
原文全文
展开原文 · 1,697 字
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit:
https://ir.revmed.com/events-and-presentations
. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit
www.revmed.com
and follow us on
LinkedIn
.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
To listen to the live webcast, or access the archived webcast, please visit:
https://ir.revmed.com/events-and-presentations
. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit
www.revmed.com
and follow us on
.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。